S. Emery

发表

Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

M. Johnson, A. Kelleher, D. Murray, 2015, PloS one.

Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.

A. Winston, S. Taylor-Robinson, D. Cooper, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictors of Clinical Progression in HIV-1-Infected Adults Initiating Combination Antiretroviral Therapy with Advanced Disease in the Asia-Pacific Region

J. Ananworanich, P. Phanuphak, S. Oka, 2013, Journal of the International Association of Providers of AIDS Care.

The Development of Artificial Neural Networks to Predict Virological response to Combination HIV Therapy

Brendan Larder, Lidia Ruiz, Andrew Revell, 2007, Antiviral therapy.

CD4+ count-guided interruption of antiretroviral treatment.

J Darbyshire, N Clumeck, J Hoy, 2006, The New England journal of medicine.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

J. Gatell, A. Phillips, B. Grund, 2008, The Journal of infectious diseases.

Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.

D. Niewoehner, J. Connett, J. Vestbo, 2016, The Lancet. Respiratory medicine.

Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH S

R. Kaiser, J. Gatell, K. Ruxrungtham, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Restorative interventions for HIV facial lipoatrophy.

S. Emery, D. Carey, S. Liew, 2008, AIDS reviews.

The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.

H. Lane, D. Cooper, J. Lundgren, 2002, Controlled clinical trials.

Why START? Reflections that led to the conduct of this large long‐term strategic HIV trial

J. Lundgren, J. Neaton, S. Emery, 2015, HIV medicine.

Demographic and HIV‐specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

J. Lundgren, S. Emery, M. Schechter, 2015, HIV medicine.

In silico thrombin generation: Plasma composition imbalance and mortality in human immunodeficiency virus

K. Brummel-Ziedins, J. Neaton, S. Emery, 2018, Research and practice in thrombosis and haemostasis.

Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial

J. Metcalf, H. Lane, A. Phillips, 2017, Open forum infectious diseases.

Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients.

K. Ruxrungtham, S. Emery, T. Bunupuradah, 2019, Pharmacogenomics.

Substantial improvements in performance indicators achieved in a PBMC cryopreservation quality assurance program using single donor samples.

S. Lewin, D. Cooper, A. Kelleher, 2006 .

Substantial Improvements in Performance Indicators Achieved in a Peripheral Blood Mononuclear Cell Cryopreservation Quality Assurance Program Using Single Donor Samples

S. Lewin, D. Cooper, A. Kelleher, 2006, Clinical and Vaccine Immunology.

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.

S. Emery, J. Amin, K. Petoumenos, 2010, The Journal of antimicrobial chemotherapy.

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

D. Cooper, P. Phanuphak, S. Khoo, 2015, Clinical Pharmacokinetics.

Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2

D. Cooper, M. Law, S. Emery, 2003, HIV clinical trials.

Changes in plasma lipidome following initiation of antiretroviral therapy

P. Meikle, P. Mundra, S. Emery, 2018, PloS one.

The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa

David P. Wilson, D. Cooper, S. Emery, 2013, PloS one.

Assessing site performance in the Altair study, a multinational clinical trial

S. Emery, R. Puls, H. Haskelberg, 2015, Trials.

Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin‐2 in a Randomized International Trial (ESPRIT)

D. Cooper, E. Lin, S. Emery, 2011, HIV medicine.

Hip Structural Parameters over 96 Weeks in HIV-Infected Adults Switching Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine

Dominic Michael Dwyer, S. Emery, J. Amin, 2014, PloS one.

Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine

S. Emery, J. Amin, P. Ebeling, 2012, PloS one.

The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV

D. Cooper, A. Kelleher, S. Emery, 2012, AIDS.

HLA Alleles Association with Changes in Bone Mineral Density in HIV-1-Infected Adults Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine

D. Cooper, A. Kelleher, S. Emery, 2014, PloS one.

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study

A. Phillips, J. Lundgren, J. Neaton, 2013, Clinical trials.

Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.

K. Ruxrungtham, D. Cooper, P. Phanuphak, 2016, The lancet. HIV.

Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial

D. Cooper, A. Kelleher, S. Emery, 2010, AIDS.

Therapy with Advanced Disease in the Asia-Pacific Region : Results from the TREAT Asia HIV Predictors of Clinical Progression in HIV-1-Infected Adults Initiating Combination Antiretroviral

P. Phanuphak, S. Oka, M. Law, 2013 .

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial

D. Cooper, H. Wand, M. Law, 2004, The Lancet.

In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.

D. Cooper, A. Kelleher, D. Chisholm, 2005, The Journal of infectious diseases.

Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapy

A. Winston, D. Cooper, D. Marriott, 2006, HIV medicine.

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia

S. Mallal, J. Kaldor, D. Cooper, 2003, HIV medicine.

Antivirals in the management of an influenza pandemic

S. Emery, D. Dwyer, M. Harrod, 2006, The Medical journal of Australia.

Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine

D. Cooper, S. Emery, J. Amin, 2011, PloS one.

Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.

D. Cooper, C. Duncombe, A. Kelleher, 1997, AIDS research and human retroviruses.

HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV

R. Center, S. Kent, A. Kelleher, 2017, Journal of Virology.

Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study

S. Khoo, S. Emery, R. Puls, 2011, Antimicrobial Agents and Chemotherapy.

Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a ‘high-affinity’ FcγRIIa genotype

A. Kelleher, M. Law, S. Emery, 2010, AIDS.

Chemokine receptor genotype and response to interleukin-2 therapy in HIV-1-infected individuals.

G. Stewart, S. Emery, P. Williamson, 2003, Clinical immunology.

A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection.

D. Cooper, A. Kelleher, J. Zaunders, 2010, AIDS research and human retroviruses.

Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting.

V. Natarajan, D. Cooper, A. Kelleher, 2013, AIDS research and human retroviruses.

Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.

S. Lewin, D. Cooper, D. Purcell, 2011, The Journal of infectious diseases.

Enfuvirtide in HIV-1-Infected Individuals Changing Therapy to A Nucleoside Reverse Transcriptase Inhibitor Sparing Regimen: The Alliance Study

D. Cooper, S. Emery, J. Amin, 2005, Antiviral therapy.

ART in HIV-positive persons with low pre-treatment viremia: results from the START trial.

S. Migueles, M. Law, S. Emery, 2019, Journal of acquired immune deficiency syndromes.

Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial

S. Emery, C. Stephan, A. Arenas-Pinto, 2019, Hepatology.

Raltegravir: a new choice in HIV and new chances for research

A. Winston, S. Emery, 2009, The Lancet.

Clinical trials of antiretroviral therapy in developing countries.

S. Emery, K. Clezy, 2000, Australian and New Zealand journal of medicine.

The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool

B. Larder, J. Montaner, S. Emery, 2011, AIDS.

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

D. Cooper, S. Emery, C. Ringland, 2004, AIDS.

Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study

M. Law, S. Emery, J. Amin, 2002, HIV clinical trials.

A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients

D. Cooper, S. Emery, K. Williams, 2009, Antiviral therapy.

The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.

A. Winston, D. Cooper, M. Law, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection

R. Davey, H. Lane, S. Kent, 2018, The Journal of infectious diseases.

Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study

T. Griffin, R. Dewar, J. Metcalf, 2017, Open forum infectious diseases.

Antiretroviral roll-out: the problem of second-line therapy

D. Cooper, S. Emery, M. Boyd, 2009, The Lancet.

Results of External Quality Assessment for Proviral DNA Testing of HIV Tropism in the Maraviroc Switch Collaborative Study

R. Kaiser, A. Kelleher, S. Emery, 2013, Journal of Clinical Microbiology.

Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.

A. Kelleher, S. Emery, K. Petoumenos, 2009, AIDS research and human retroviruses.

Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial—The ENCORE1 Study

S. Khoo, S. Emery, J. Amin, 2017, Therapeutic drug monitoring.

Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015

R. Schooley, E. Maltezos, Tak-chiu Wu, 2017, Open forum infectious diseases.

Bone turnover markers in HIV disease.

S. Emery, A. Carr, H. Haskelberg, 2011, AIDS reviews.

Metabolic Profiles of Individuals Switched to Second-Line Antiretroviral Therapy after Failing Standard First-Line Therapy for Treatment of HIV-1 Infection in a Randomized, Controlled Trial

D. Cooper, S. Kerr, S. Emery, 2017, Antiviral therapy.

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

D. Cooper, P. Phanuphak, S. Emery, 2013, AIDS.

Short Communication: Nonnucleoside Reverse Transcriptase Inhibitor Fold Change or Plasma Concentration as a Predictor of Virological Response over 48 Weeks in Highly Treatment Experienced HIV-Positive Individuals

A. Winston, D. Cooper, S. Emery, 2006 .

Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [co

H. Wand, M. Law, S. Emery, 2007, Diabetes care.

Bone Mineral Density Over 96 Weeks in Adults Failing First-Line Therapy Randomized to Raltegravir/Lopinavir/Ritonavir Compared With Standard Second-Line Therapy

D. Cooper, P. Phanuphak, S. Emery, 2014, Journal of acquired immune deficiency syndromes.

Immune‐based therapies in HIV infection: recent developments

H. Lane, S. Emery, 1996, AIDS.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

H. Lane, D. Cooper, A. Phillips, 2015, The New England journal of medicine.

Role of Interleukin-2 in Patients with HIV Infection

A. Kelleher, S. Emery, S. Pett, 2012, Drugs.

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

D. Hazuda, D. Cooper, H. Teppler, 2007, AIDS.

Dose-Response Relationship of DNA and Recombinant Fowlpox Virus Prime-Boost HIV Vaccines: Implications for Future Trials

D. Cooper, S. Kent, A. Kelleher, 2006, Human vaccines.

Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy

A. Winston, S. Taylor-Robinson, D. Cooper, 2012, Neuroradiology.

A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Potential in HIV Infection

S. Emery, E. Clercq, M. Kline, 1996 .

Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa

Zonghui Hu, S. Emery, S. Orsega, 2011, AIDS.

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

D. Cooper, S. Emery, J. Amin, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.

A. Winston, D. Cooper, D. Marriott, 2005, Journal of Antimicrobial Chemotherapy.

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

M. Bebbington, D. Cooper, D. Purcell, 2006, AIDS (London).

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study

D. Cooper, P. Phanuphak, S. Khoo, 2015, Clinical pharmacology and therapeutics.

Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability

H. Jäck, A. Kelleher, K. J. Jackson, 2021, Immunity.

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

D. Cooper, M. Law, S. Emery, 2000, AIDS.

Effect of nucleoside reverse transcriptase inhibitors on CD4 T‐cell recovery in HIV‐1‐infected individuals receiving long‐term fully suppressive combination antiretroviral therapy

D. Cooper, S. Emery, K. Petoumenos, 2009, HIV medicine.

CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.

D. Cooper, A. Kelleher, M. Law, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Simplification with fixed-dose Tenofovir-Emtricitabine or Abacavir-Lamivudine in treatment experienced, virologically suppressed adults with Hiv infection: combined analysis of two randomised, non-inferiority trials Bicombo and Steal

D. Cooper, S. Emery, E. Martinez, 2010 .

Interleukin-2 therapy in patients with HIV infection.

H. Lane, D. Cooper, A. Phillips, 2009, The New England journal of medicine.

Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.

H. Jessen, A. Winston, D. Cooper, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

B. Gazzard, D. Cooper, P. Phanuphak, 2014, The Lancet.

Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Handan Wand, Sean Emery, Daniel E Nixon, 2011, The Journal of infectious diseases.

An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection

K. Ruxrungtham, D. Cooper, S. Sirivichayakul, 2010, Human vaccines.

Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12.

D. Cooper, D. Purcell, S. Kent, 2004, Vaccine.

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

H. Jessen, A. Winston, D. Cooper, 2015, The Lancet. Infectious diseases.

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

B. Gazzard, S. Khoo, S. Emery, 2011, The Journal of antimicrobial chemotherapy.

A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies, PEHRG214, in HIV-1--Infected Individuals

R. Day, S. Lewin, S. Emery, 2004, HIV clinical trials.

Differences in the Direction of Change of Cerebral Function Parameters Are Evident over Three Years in HIV-Infected Individuals Electively Commencing Initial cART

A. Winston, S. Taylor-Robinson, D. Cooper, 2015, PLoS ONE.

Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study

S. Emery, B. Angus, J. Baker, 2013, PloS one.

Immunomodulators as adjunctive therapy for HIV-1 infection.

S. Emery, S. Pett, 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Effects of IL‐2 therapy in asymptomatic HIV‐infected individuals on proliferative responses to mitogens, recall antigens and HIV‐related antigens

A. Kelleher, S. Emery, M. French, 1998, Clinical and experimental immunology.

Therapeutic vaccination against HIV: current progress and future possibilities.

S. Emery, R. Puls, 2006, Clinical science.

Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels

V. Natarajan, D. Cooper, A. Kelleher, 2015, AIDS.

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease.

J. Kovacs, H. Lane, D. Cooper, 2000, The Journal of infectious diseases.

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

R. Davey, H. Lane, H. Salomón, 2000, The Journal of infectious diseases.

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group.

G. Stewart, D. Cooper, S. Emery, 1998, The Journal of infectious diseases.

Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts

D. Cooper, S. Kent, A. Kelleher, 2017, Journal of acquired immune deficiency syndromes.

Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption

D. Cooper, M. Davenport, S. Kent, 2017, Journal of Virology.

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

K. Ruxrungtham, D. Cooper, H. Teppler, 2015, The lancet. HIV.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

A. Phillips, J. Lundgren, W. El-Sadr, 2008, The Journal of infectious diseases.

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

A. Phillips, J. Lundgren, W. El-Sadr, 2008, Annals of internal medicine.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen

Z. Fox, B. Hirschel, A. Phillips, 2008, AIDS.

Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.

D. Cooper, A. McNulty, A. Kelleher, 2018, The lancet. HIV.

Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

B. Gazzard, D. Cooper, C. Duncombe, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection

B. Grund, S. Emery, E. Gardner, 2017, AIDS.

HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting

K. Ruxrungtham, D. Cooper, P. Phanuphak, 2005, AIDS.

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV‐Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial

B. Gazzard, E. Soliman, A. Phillips, 2017, Journal of the American Heart Association.

Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial

H. Furrer, J. Lundgren, J. Boatman, 2019, Journal of acquired immune deficiency syndromes.

Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4+ Counts > 500 cells/mm 3 : Findings from the Strategic Timing of AntiRetroviral Treatment (START) Trial

H. Furrer, J. Lundgren, J. Boatman, 2022 .

Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting

B. Hirschel, J. Ananworanich, K. Ruxrungtham, 2008, International journal of STD & AIDS.

Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients

D. Cooper, J. Neaton, M. Law, 2010, AIDS.

A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard Study

R. Davey, H. Lane, M. Youle, 2006, PLoS clinical trials.

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferio

D. Cooper, H. Teppler, S. Kerr, 2013, The Lancet.

Influence of IFNγ Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following Interruption of Antiretroviral Therapy

A. Kelleher, S. Emery, R. Puls, 2007, Human vaccines.

Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial.

S. Kent, A. Kelleher, M. Law, 2018, The lancet. HIV.

Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data

S. Hammer, B. Gazzard, L. Bacheler, 2008, Journal of acquired immune deficiency syndromes.

The search for an HIV cure: tackling latent infection.

S. Lewin, D. Cooper, J. Reece, 2013, The Lancet. Infectious diseases.

HIV dynamics linked to memory CD4+ T cell homeostasis

D. Cooper, A. Kelleher, J. Zaunders, 2017, PloS one.

Poly‐l‐lactic acid for HIV‐1 facial lipoatrophy: 48‐week follow‐up

S. Emery, K. Petoumenos, A. Carr, 2009, HIV medicine.

A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy

D. Cooper, S. Emery, K. Petoumenos, 2007, Journal of acquired immune deficiency syndromes.

Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial

D. Cooper, H. Wand, S. Emery, 2005, AIDS.

CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.

R. Davey, H. Lane, K. Ruxrungtham, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immune reconstitution in HIV infection.

H. Lane, S. Emery, 1997, Current opinion in immunology.

Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria

H. Wand, M. Law, S. Emery, 2007, Diabetes Care.

Predicting the potential benefits of early initiation of ART: time to do a trial to find out.

A. Phillips, S. Emery, 2009, Current opinion in HIV and AIDS.

Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.

D. Cooper, H. Teppler, S. Emery, 2016, AIDS research and human retroviruses.

Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults

D. Cooper, A. Kelleher, S. Emery, 2010 .

Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection.

D. Cooper, S. Emery, 1995, Australian and New Zealand Journal of Medicine.

Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral therapy

S. Emery, Allison Martin, 2009, Expert review of clinical pharmacology.

High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40)1

D. Cooper, S. Kent, A. Kelleher, 2009, The Journal of Immunology.

Dynamics of cognitive change in HIV‐infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study

A. Winston, S. Taylor-Robinson, C. Duncombe, 2012, HIV medicine.

A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults

D. Cooper, H. Wand, S. Emery, 2012, Journal of acquired immune deficiency syndromes.

Influence of Rosiglitazone on Flow-Mediated Dilation and Other Markers of Cardiovascular Risk in HIV-Infected Patients with Lipoatrophy

D. Cooper, H. Wand, J. Kovacic, 2005, Antiviral therapy.

after endotoxin challenge in humans Gene expression profiles of peripheral blood leukocytes

P. Munson, S. Lewin, J. Brenchley, 2011 .

Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV

S. Emery, P. Ebeling, M. Kimlin, 2016, Osteoporosis International.

Pre‐therapy inflammation and coagulation activation and long‐term CD4 count responses to the initiation of antiretroviral therapy

H. Furrer, A. Phillips, S. Emery, 2015, HIV medicine.

Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010

Sean Emery, James D. Neaton, J. Neaton, 2010, Current opinion in HIV and AIDS.

If it's the virus, why aren't we measuring it?

D. Cooper, S. Emery, A. Carr, 1995, The Medical journal of Australia.

Antiretro viral therapy of human immunodeficiency virus type-1 (HIV-1) infection

D. Cooper, S. Emery, 1995 .

A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.

Michael A. Polis, J. Neaton, S. Emery, 2010, The Journal of infectious diseases.

Lipodystrophy following antiretroviral therapy of primary HIV infection.

D. Cooper, M. Law, S. Emery, 2000, AIDS.

Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.

D. Cooper, A. Kelleher, S. Emery, 2008, The Journal of infectious diseases.

A Randomised Trial Comparing Genotypic and Virtual Phenotypic Interpretation of HIV Drug Resistance: The CREST Study

A. Kelleher, M. Law, S. Emery, 2006, PLoS clinical trials.

Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir

V. Natarajan, D. Cooper, A. Kelleher, 2011, AIDS.

Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial

H. Jessen, D. Duprez, K. H. Hullsiek, 2016, Open forum infectious diseases.

2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

B. Gazzard, R. Kaiser, B. Larder, 2021, The Journal of antimicrobial chemotherapy.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings

Dechao Wang, Shanmugam Saravanan, John Baxter, 2018, The Journal of antimicrobial chemotherapy.

Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards

D. Cooper, A. Kelleher, J. Zaunders, 2012, AIDS.

HIV DNA Subspecies Persist in both Activated and Resting Memory CD4+ T Cells during Antiretroviral Therapy

D. Cooper, A. Kelleher, J. Zaunders, 2014, Journal of Virology.

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

D. Cooper, P. Phanuphak, S. Emery, 2013, PloS one.

Therapeutic strategies for HIV infection--time to think hard.

D. Cooper, S. Emery, 1998, The New England journal of medicine.

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

D. Cooper, H. Teppler, S. Kerr, 2015, PloS one.

Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection

D. Cooper, H. Wand, M. Law, 2007, AIDS.

The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis

J. Lundgren, J. Neaton, S. Emery, 2018, The Journal of infectious diseases.

Stimulated Coexpression of CD 25 and T Cells in Peripheral Blood Revealed by + High Levels of Human Antigen-Specific CD 4

D. Cooper, S. Kent, A. Kelleher, 2009 .

Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals

M. Johnson, A. Kelleher, D. Murray, 2017, Scientific Reports.

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy

D. Cooper, P. Phanuphak, S. Emery, 2017, The lancet. HIV.

Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison

J. Gatell, K. Ruxrungtham, A. Phillips, 2019, AIDS (London).

The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals

A. Winston, D. Cooper, S. Emery, 2005, AIDS.

Limited Evolution of HIV Antiretroviral Drug Resistance-Associated Mutations During the Performance of Drug Resistance Testing

D. Cooper, M. Law, S. Emery, 2003, Journal of acquired immune deficiency syndromes.

Quality Assessment Program for Genotypic Antiretroviral Testing Improves Detection of Drug Resistance Mutations

F. Christiansen, S. Emery, M. French, 2003, Journal of Clinical Microbiology.

HIV medicine

Sean Emery, D. Cooper, S. Emery, 2002, The Medical journal of Australia.

Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial

H. Wand, S. Emery, F. Hudson, 2009, AIDS.

Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism.

D. Cooper, H. Wand, M. Law, 2009, Current HIV research.

Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic

Henrik Nielsen, L. Mathiesen, C. Leen, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization

J. Powers, J. Neaton, S. Emery, 2017, Clinical trials.

Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals

H. Chu, L. Kuller, C. Sabin, 2012, AIDS.

Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison

J. Gatell, K. Ruxrungtham, A. Phillips, 2019, AIDS.

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.

R. Paredes, H. Furrer, A. Phillips, 2023, NEJM evidence.

Disease progression and fatal outcomes in HIV-infected patients during interruption of antiretroviral treatment.

D. Cooper, S. Emery, D. Cordery, 2008, The Journal of infectious diseases.

Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa

B. Larder, P. Reiss, S. Emery, 2016, Southern African journal of HIV medicine.

An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.

A. Wensing, B. Larder, J. Montaner, 2014, The Journal of antimicrobial chemotherapy.

The impact of registration of clinical trials units: The UK experience

S. Emery, J. Darbyshire, J. Pater, 2015, Clinical trials.

A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand

S. Suwanagool, R. Davey, H. Lane, 2000, AIDS.

Prospective evidence that HIV lipoatrophy and visceral adiposity are partially independent processes

D. Cooper, H. Wand, M. Law, 2011 .

Randomised, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-? in HIV-1 Infected Subjects

A. Kelleher, S. Emery, R. Puls, 2005, Human vaccines.

A Comparison of Three Computational Modelling Methods for the Prediction of Virological Response to Combination Hiv Therapy Author's Personal Copy

Brendan Larder, Dechao Wang, Lidia Ruiz, 2022 .

Latent reservoirs of HIV infection: Flushing with IL-2?

D. Cooper, S. Emery, 1999, Nature Medicine.

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

T. Harrer, A. Winston, E. Harrer, 2023, Scientific Reports.

Edinburgh Research Explorer Impact of early antiretroviral treatment on sexual behaviour in the INSIGHT Strategic Timing of Anti-Retroviral Treatment (START) Trial

J. Gatell, K. Ruxrungtham, A. Phillips, 2019 .

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial Network for Strategic Initiatives in Global HIV Trials) START (Strategic of Antiretroviral

A. Phillips, S. Spector, S. Emery, 2018 .

Title : Benefit of early versus deferred antiretroviral therapy on progression of liver fibrosis among people with HIV in the START randomized trial

S. Emery, C. Stephan, A. Arenas-Pinto, 2018 .

ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.

S. Migueles, M. Law, S. Emery, 2019, Journal of acquired immune deficiency syndromes.

In silico thrombin generation INSIGHT SMART, ESPRIT Study Groups

S. Emery, D. Chadwick, Á. Borges, 2018 .

Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals

M. Johnson, A. Kelleher, Kazuo Suzuki, 2017, Scientific Reports.

The search for an HIV cure: tackling latent infection.

S. Lewin, D. Cooper, J. Reece, 2013, The Lancet. Infectious diseases.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

A. Phillips, J. Lundgren, W. El-Sadr, 2008, The Journal of infectious diseases.

Selective exclusion of treatment arms in multi‐arm randomized clinical trials

S. Emery, M. Law, 2003, Statistics in medicine.

Plasma levels of soluble CD14 independently predict mortality in HIV infection.

S. Lewin, D. Douek, J. Brenchley, 2011, The Journal of infectious diseases.

A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy

A. d’Arminio Monforte, B. Larder, J. Montaner, 2009, Artif. Intell. Medicine.

Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.

D. Cooper, A. McNulty, A. Kelleher, 2018, The lancet. HIV.

HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV

A. Kelleher, S. Emery, J. Amin, 2017, Journal of Virology.

HLA Alleles Association with Changes in Bone Mineral Density in HIV-1-Infected Adults Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine

A. Kelleher, S. Emery, J. Amin, 2014, PloS one.

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

K. Ruxrungtham, D. Cooper, H. Teppler, 2015, The lancet. HIV.

Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization

J. Powers, J. Neaton, S. Emery, 2017, Clinical trials.

Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors

Praphan Phanuphak, Joep Lange, Sean Emery, 2003, AIDS.

The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV

D. Cooper, A. Kelleher, S. Emery, 2012, AIDS.

Three-Year Durability of Dual-Nucleoside Versus Triple-Nucleoside Therapy in a Thai Population With HIV Infection

K. Ruxrungtham, D. Cooper, P. Phanuphak, 2004, Journal of acquired immune deficiency syndromes.

Potential implications of CYP 3 A 4 , CYP 3 A 5 and MDR-1 genetic variants on the efficacy of Lopinavir / Ritonavir ( LPV / r ) monotherapy in HIV-1 patients

H. Jessen, A. Winston, D. Cooper, 2022 .